Taysha GTx Valuation Multiples

Taysha GTx Overview

About Taysha GTx

Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.

Founded

2019

HQ

Employees

73

Website

tayshagtx.com

Sectors

BiopharmaceuticalsBioTechDeepTech

Financials (LTM)

Revenue: $8M

EBITDA: ($118M)

EV

$1B

Valuation Multiples

Multiples.vc

Start free trial

Taysha GTx Financials

Taysha GTx reported last 12-month revenue of $8M and negative EBITDA of ($118M).

In the same LTM period, Taysha GTx generated $8M in gross profit, ($118M) in EBITDA losses, and had net loss of ($116M).

Taysha GTx P&L

In the most recent fiscal year, Taysha GTx reported revenue of $8M and EBITDA of ($88M).

Taysha GTx expects next 12-month revenue of XXX and NTM EBITDA of XXX

Taysha GTx Stock Performance

Taysha GTx has current market cap of $1B, and enterprise value of $1B.

Taysha GTx's stock price is $4.63.

Taysha GTx Valuation Multiples

Taysha GTx trades at 123.6x EV/Revenue multiple, and (8.8x) EV/EBITDA.

Taysha GTx Financial Valuation Multiples

As of March 21, 2026, Taysha GTx has market cap of $1B and EV of $1B.

Equity research analysts estimate Taysha GTx's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Taysha GTx has a P/E ratio of (10.9x).

Taysha GTx Margins & Growth Rates

Taysha GTx's revenue in the last 12 month grew by 23%.

Taysha GTx's revenue per employee in the last FY averaged $0.1M.

Taysha GTx's rule of 40 is (1382%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Taysha GTx's rule of X is (1347%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Taysha GTx Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Taysha GTx M&A Activity

Taysha GTx acquired XXX companies to date.

Last acquisition by Taysha GTx was on XXXXXXXX, XXXXX. Taysha GTx acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Taysha GTx Investment Activity

Taysha GTx invested in XXX companies to date.

Taysha GTx made its latest investment on XXXXXXXX, XXXXX. Taysha GTx invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).